Annex 2: List of participants

Mr J. Bell, 6 Oxford Street, Woollahra NSW 2025, Australia.

Ms S.M. Chang, Pharmaceutical Society of Singapore, Alumni Medical Centre, Second Level, 2 College Road, Singapore 169850.

Prof H. Die-Kacou, BP V 166, Abidjan, Côte d’Ivoire.

Prof J.P. Grégoire, Faculté de Pharmacie, Université Laval, Québec, QC, Canada G1K 7P4.

Mrs S. Hutangkabodee, Technical Division, FDA, Ministry of Public Health, Twanond Road, Nonhtaburi 11000, Thailand.

Dr M. Lakhal*, Faculté de Médecine de Tunis, 9 rue du Pr. Zouhair Essafi, 1006 Tunis, Tunisia.

* Unable to attend

Dr C. Mbi, Pharmacie du Stade, P.M.B. 6182 Yaoundé, Cameroon.

Mrs E. Osei, Police Hospital, Pharmacy Department, P.O. Box 116, Accra, Ghana.

Dr D. Steinbach, Hof-Apotheke, Louisenstrasse 55, 61348 Bad Homburg, Germany.

WHO/DAP regional advisers

Dr A. Alwan*, Director, DHS, World Health Organization, Regional Office for the Eastern Mediterranean, P.O. Box 1517, Alexandria 21511, Egypt.

* Unable to attend

Dr M. Chisale, DAP regional adviser, EDV, World Health Organization, Regional Office for Africa, P.O. Box BE 773, Belvedere, Harare, Zimbabwe.

Mr C.P. de Joncheere, RA/PHA, World Health Organization, Regional Office for Europe, 8, Scherfigsvej, 2100 Copenhagen Ø, Denmark.

Speakers

Mr J. Ferguson, The Royal Pharmaceutical Society of Great Britain, 1 Lambeth High Street, London SE1 7JN, United Kingdom.

Ms S. Kelly, World Self Medication Industry (WSMI), Vernon House, Sicilian Avenue, London WC1A 2QH, United Kingdom.

Dr R.O. Laing, Boston University, School of Public Health, 715 Albany Street, Boston, MA 02118-2526, United States of America.

Dr F. Martin, West Prince Pharmacy, 504 Main Street, PO Box 57, O’Leary, Prince Edward Island, Canada C0B 1V0.

Ms M. Murray, Hodge Murray Hodge Pty Ltd., 42 Urambi Village, Crozier Circuit, Kambah, ACT 2902, Australia.

Ms E. ‘t Hoen (HAI), Prescrire International, BP 459, F-75527 Paris Cedex 11, France.

Mrs M. Torongo, P.O. Box M 28, Harare, Zimbabwe.

Representatives of other organizations

American Pharmaceutical Association (APhA)*

*Unable to attend

Commonwealth Pharmaceutical Association (CPA)

Mr M. Sesay, UNICEF/Freetown, Sierra Leone.

European Pharmaceutical Students’ Association (EPSA)

Mr I. Monteagudo, EPSA c/o PGEU; Square Ambiorix Brussels, Belgium.

EuroPharm Forum

Ms I. Gustafsen, c/o World Health Organization, Regional Office for Europe, 8, Scherfigsvej, 2100 Copenhagen Ø, Denmark.

International Pharmaceutical Federation (IPF)

Ms B. Frokjaer (Rapporteur), Danmarks Apotekerforening, Bredgade 54, Postboks 2181, 1017 Copenhagen K, Denmark.

Dr N.O Strandqvist, Regional Advisor, Botvidsgatan 41, 75329 Uppsala, Sweden.

International Pharmaceutical Students Federation (IPSF)

Ms A. Sutherland, Andries Bickerweg 5, 2517 The Hague, The Netherlands.

World Self Medication Industry (WSMI)

Mr E. Gezzi, WSMI Vice Chairman Latin America, Secretary General Latin American OTC Association, Laboratorios EJ Gezzi SRL, Guevara 1347, 1427 Buenos Aires, Argentina.

Dr J.A. Reinstein, Director General, WSMI, 15 Sydney House, Woodstock Road, London W4 1DP, United Kingdom.

Ms J. Seifert, Executive Director, Proprietary Medicines Association of Australia Inc (PMAA) Level 4, 140 Arthur Street, North Sydney NSW 2060, Australia.

Secretariat

Dr B.B. Betts, Consultant, Action Programme on Essential Drugs ³, WHO, Geneva.

Dr M. Demesmaeker, Division of Drug Management and Policies, WHO, Geneva.

Mr P. Spivey, Technical Officer, Action Programme on Essential Drugs, WHO, Geneva.

³ The Essential Drugs and Other Medicines Department (EDM) includes the former Action Programme on Essential Drugs (DAP) and most components of the former Division of Drug Management and Policies (DMP).